Abstract
Question addressed Echocardiography is not currently considered as providing sufficient prognostic information to serve as an integral part of treatment goals in pulmonary arterial hypertension (PAH). We tested the hypothesis that incorporation of multiple parameters reflecting right heart function would improve the prognostic value of this imaging modality.
Methods and Main Results We pooled individual patient data from a total of 517 patients (mean age 52±15 years, 64.8% females) included in seven observational studies conducted at five European and United States academic centers. Patients were subdivided into three groups representing progressive degrees of RV dysfunction based on a combination of echocardiographic measurements: group 1 (low-risk): normal tricuspid annular plane systolic excursion (TAPSE) and non-significant tricuspid regurgitation (TR) (n=129); group 2 (intermediate-risk): normal TAPSE and significant TR or impaired TAPSE and non-dilated inferior vena cava (IVC) (n=256); group 3 (high-risk): impaired TAPSE and dilated IVC (n=132). The 5-year cumulative survival rate was 82% in group 1, 63% in group 2, and 43% in group 3. Low-risk patients had better survival rates than intermediate-risk patients (log-rank χ2: 12.25 p<0.001) and intermediate-risk patients had better survival rates than high-risk patients (log-rank χ2: 26.25 p<0.001). Inclusion of other parameters such as right atrial area and pericardial effusion did not provide added prognostic value.
Answer to the question The proposed echocardiographic approach integrating the evaluation of TAPSE, TR grade and IVC is effective in stratifying the risk for all-cause mortality in PAH patients, outperforming the prognostic parameters suggested by current guidelines.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Ghio has nothing to disclose.
Conflict of interest: Dr. Mercurio has nothing to disclose.
Conflict of interest: Dr. Fortuni has nothing to disclose.
Conflict of interest: Dr. Forfia has nothing to disclose.
Conflict of interest: Dr. Gall has nothing to disclose.
Conflict of interest: Dr. Ghofrani has nothing to disclose.
Conflict of interest: Dr. Mathai has nothing to disclose.
Conflict of interest: Dr. Mazurek has nothing to disclose.
Conflict of interest: Dr. Mukherjee has nothing to disclose.
Conflict of interest: Dr. Richter has nothing to disclose.
Conflict of interest: Dr. Scelsi has nothing to disclose.
Conflict of interest: Dr. Hassoun has nothing to disclose.
Conflict of interest: Dr. Tello has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received March 2, 2020.
- Accepted May 7, 2020.
- Copyright ©ERS 2020